Back to Results
First PageMeta Content
Alcohols / Pharmaceutical industry / Pharmacy / Merck & Co. / Vernakalant / DeCODE genetics / Pharmaceutical sciences / Pharmacology / Dow Jones Industrial Average


MANAGEMENT DISCUSSION & ANALAYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Add to Reading List

Document Date: 2014-08-12 16:28:19


Open Document

File Size: 107,81 KB

Share Result on Facebook

City

Geneva / Vienna / /

Company

BRINAVESS / Tamro AB / Cormark Securities Inc. / UDG Healthcare PLC / ACS / Nomeco A/S / Logista Pharma S.A. / MLV & Co. LLC / Canaccord Genuity Corp. / Merck / Astellas Pharma US Inc. / Correvio LLC / VIANEX S.A. / MidCap Financial LLC / CarCor Investment Holdings LLC / Merck Sharp & Dohme Corp. / AOP Orphan Pharmaceuticals AG / Cardiome Pharma Corp. / /

Continent

North America / Europe / /

Country

Switzerland / Romania / Hungary / Slovenia / Sweden / Latvia / Poland / Norway / Austria / United States / Iceland / Canada / Slovakia / Spain / Greece / Ireland / Denmark / Czech Republic / /

Currency

USD / CAD / /

Event

Business Partnership / M&A / Reorganization / FDA Phase / Layoffs / Funding / /

Facility

CORPORATE UPDATE Senior Secured Term Loan Facility / /

IndustryTerm

partner network / pharmaceutical / healthcare systems / promotional services / cardiology products / clinical trial accounting / vernakalant products / co-lead underwriter / manufacturing / /

MedicalCondition

chest pain / indicated Acute Coronary Syndrome / contraction of muscles / human disorders / heart disease / blood clots / heart attacks / ST-elevation myocardial infarction / non-ST-elevation myocardial infarction / onset atrial fibrillation / Acute Coronary Syndrome / minimal / structural heart disease / heart failure / heart attack / cardiogenic shock / atrial fibrillation / Acute Coronary Syndrome AGGRASTAT / inflammation / /

MedicalTreatment

cardiac surgery / surgery / cardioversion / /

Organization

European Society of Cardiology / Committee for Medicinal Products for Human Use / U.S. Securities and Exchange Commission / European Medicines Agency / U.S. Food and Drug Administration / European Commission / European Union / /

Position

general corporate expenditures / co-lead underwriter / bookrunner and co-lead underwriter / General / general corporate purposes / /

Product

AGGRASTAT / European Union / Q3-2008 / BRINAVESSTM / Q2-2010 / /

ProvinceOrState

Indiana / /

Region

Asia Pacific / /

Technology

ATM / pharmacokinetics / pharmacodynamics / CAD / /

URL

www.sedar.com / www.sec.gov/edgar / /

SocialTag